HRP20190988T1 - Nova protutijela protiv fosforilkolina - Google Patents
Nova protutijela protiv fosforilkolina Download PDFInfo
- Publication number
- HRP20190988T1 HRP20190988T1 HRP20190988TT HRP20190988T HRP20190988T1 HR P20190988 T1 HRP20190988 T1 HR P20190988T1 HR P20190988T T HRP20190988T T HR P20190988TT HR P20190988 T HRP20190988 T HR P20190988T HR P20190988 T1 HRP20190988 T1 HR P20190988T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence
- antibody
- Prior art date
Links
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 title claims 5
- 229950004354 phosphorylcholine Drugs 0.000 title claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 53
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 27
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 27
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- IMPUTFHEGODHBK-UHFFFAOYSA-N [2-aminooxy-2-[oxido(phenyl)phosphaniumylidene]ethyl]-trimethylazanium Chemical compound C[N+](C)(C)CC(ON)=P(=O)C1=CC=CC=C1 IMPUTFHEGODHBK-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Claims (15)
1. Humano protutijelo ili fragment protutijela koji ima mogućnost vezanja na fosforilkolin naznačen time da protutijelo ili fragment protutijela sadrži varijabilnu domenu teškog lanca (VH) i varijabilnu domenu lakog lanca (VL), pri čemu
(a) VH domena sadrži aminokiselinsku sekvencu koja uključuje tri regije koje određuju komplementarnost (CDR) koje se sastoje od:
CDR1 sekvence koja sadrži sekvencu aminokiseline koja ima najmanje 75% ili 100% istovjetnosti sekvence u sekvenci SEQ ID NO:17;
CDR2 sekvence koja sadrži sekvencu aminokiseline koja sadrži najmanje 94% ili 100% istovjetnosti sekvence u sekvenci SEQ ID NO:18; i
CDR3 sekvence koja sadrži sekvencu aminokiseline koja sadrži najmanje 95% ili 100% istovjetnosti sekvence u SEQ ID NO: 19, 20, 21 ili 22; i
(b) VL domena sadrži sekvencu aminokiseline koja uključuje tri regije koje određuju komplementarnost (CDR) koje se sastoje od:
CDR4 sekvence koja sadrži sekvencu aminokiseline koja ima najmanje 94% ili 100% istovjetnosti sekvence u SEQ ID NO:23 ili 24;
CDR5 sekvence koja sadrži sekvencu aminokiseline koja sadrži najmanje 85% ili 100% istovjetnosti sekvence u SEQ ID NO:25;
CDR6 sekvence koja sadrži sekvencu aminokiseline koja sadrži najmanje 88% ili 100% istovjetnosti sekvence u SEQ ID NO:26,
gdje se protutijelo ili fragment protutijela veže na imobiliziran aminofenil-fosforilkolin sa Kd ne višom od 500nM, testirano pod uvjetima rezonancije površinskih plazmona korištenih u primjerima.
2. Protutijelo ili fragment protutijela prema zahtjevu 1 naznačen time da
(a) CDR1 sekvenca sadrži sekvencu aminokiseline od SEQ ID NO: 17;
CDR2 sekvenca sadrži sekvencu aminokiseline od SEQ ID NO: 18; i
CDR3 sekvenca sadrži sekvencu aminokiseline od SEQ ID NO: 19, 20, 21 ili 22, i
(b) CDR4 sekvenca sadrži sekvencu aminokiseline od SEQ ID NO: 23 ili 24;
CDR5 sekvenca sadrži sekvencu aminokiseline od SEQ ID NO: 25;
CDR6 sekvence sadrži sekvencu aminokiseline iz SEQ ID NO: 26.
3. Protutijelo ili fragment protutijela prema bilo kojem prethodnom zahtjevu, naznačen time da - VH domena sadrži sekvencu aminokiseline odabranu iz skupine koja se sastoji od SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 i 15 ili sekvence aminokiseline koja ima najmanje 80%, 85%, 90% ili 95% istovjetnosti sekvence u sekvenci aminokiseline od bilo koje SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 ili 15, i VL domena sadrži sekvencu aminokiseline odabranu iz skupine koja se sastoji od SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 ili 16 ili sekvence aminokiseline koja ima najmanje 80%, 85%, 90% ili 95% istovjetnosti sekvence od bilo koje od SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 ili 16,
4. Protutijelo ili fragment protutijela prema bilo kojem od prethodnih zahtjeva, naznačen time da - (VH) domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 1, i
VL domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 2;
VH domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 3, i
VL domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 4;
VH domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 5, i
VL domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti SEQ ID NO: 6;
VH domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 7, i
VL domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 8, i
VH domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti SEQ ID NO:9,
VL domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 10, i
VH domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 11, i
VL domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 12;
VH domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 13, i
VL domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 14, ili
VH domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 15, i
VL domena sadrži sekvencu aminokiseline koja ima najmanje 80%, 85%, 90%, 95% ili 100% istovjetnosti sekvence SEQ ID NO: 16;
5. Protutijelo ili fragment protutijela prema zahtjevu 3 ili 4, naznačen time da VH domena, VL domena, ili poželjno obje od VH i VL domena, sadrže sekvencu aminokiseline koja ima 100% istovjetnosti sekvence na navedenoj SEQ ID NO.; ili
VH domena, VL domena, ili obje od VH i VL domena, sadrže sekvencu aminokiseline koja ima manje od 100%, ali najmanje od 90%, 95%, istovjetnosti na jednu ili svaku, navedenu SEQ ID NO.
6. Humano protutijelo ili fragment protutijela koji ima mogućnost vezanja na fosforilkolin, naznačen time da protutijelo ili njegov fragment sadrži varijabilnu domenu teškog lanca (VH) i domenu lakog lanca (VL), a pri ćemu
VH domena sadrži sekvencu aminokiseline iz SEQ ID NO: 3, i
VL domena sadrži sekvencu aminokiseline iz SEQ ID NO: 4;
VH domena sadrži sekvencu aminokiseline iz SEQ ID NO: 5, i
VL domena sadrži sekvencu aminokiseline iz SEQ ID NO: 6;
VH domena sadrži sekvencu aminokiseline iz SEQ ID NO: 7, i
VL domena sadrži sekvencu aminokiseline iz SEQ ID NO: 8;
VH domena sadrži sekvencu aminokiseline iz SEQ ID NO: 9, i
VL domena sadrži sekvencu aminokiseline iz SEQ ID NO: 10;
VH domena sadrži sekvencu aminokiseline iz SEQ ID NO: 11, i
VL domena sadrži sekvencu aminokiseline iz SEQ ID NO: 12;
VH domena sadrži sekvencu aminokiseline iz SEQ ID NO: 13 i
VL domena sadrži sekvencu aminokiseline iz SEQ ID NO: 14; ili
VH domena sadrži sekvencu aminokiseline iz SEQ ID NO: 15, i
VL domena sadrži sekvencu aminokiseline iz SEQ ID NO: 16.
7. Protutijelo ili fragment protutijela prema zahtjevu 6, naznačen time da VH domena sadrži sekvencu iz SEQ ID NO:1, vezanu na CH područje iz SEQ ID NO: 28 i VL domena sadrži sekvencu iz SEQ ID NO:2 vezanu za CL područje iz SEQ ID NO:29.
8. Farmaceutski pripravak koji sadrži protutijelo ili fragment protutijela prema bilo kojem od prethodnih zahtjeva, naznačen time da je nosač ili farmaceutski prihvatljiv ekscipijens, pri čemu opcijski jedina protutijela ili fragmenti protutijela prisutni u pripravku su oni koji su definirani prema prethodnim zahtjevima.
9. Protutijelo ili fragment protutijela prema bilo kojem od zahtjeva 1 do 7, ili farmaceutski pripravak prema zahtjevu 8, naznačen time da se koristi u medicini.
10. Protutijelo ili fragment protutijela prema bilo kojem od zahtjeva 1 do 7, ili farmaceutski pripravak prema zahtjevu 8, naznačen time da je za upotrebu u:
prevenciji, profilaksi i/ili liječenju sisavaca, uključujući ljude, protiv ateroskleroze, bolesti povezane s aterosklerozom ili kardiovaskularne bolesti, pri ćemu opcijski kardiovaskularna bolest je odabrana iz skupine koja se sastoji od ateroskleroze, akutnog koronarnog sindroma, infarkta miokarda (srčani udar), stabilne i nestabilne angine pektoris, aneurizma, od koronarne bolesti srca (CAD), ishemijske bolesti srca, ishemijskog miokarda, kardiovaskularne smrti i iznenadne kardiovaskularne smrti, kardiomiopatije, kongestivnog zatajenja srca, zatajenja srca, stenoze, periferne arterijske bolesti (PAD), intermitentne klaudikacije, akutne ishemije udova i moždanog udara.
11. Sekvenca nukleinske kiseline, naznačena time da kodira protutijelo ili fragment protutijela prema bilo kojem zahtjevu 1 do 7.
12. Vektor ili plazmid naznačen time da sadrži sekvencu nukleinske kiseline prema zahtjevu 11.
13. Stanica domaćina naznačen time da sadrži sekvencu nukleinske kiseline prema zahtjevu 11 i/ili vektor ili plazmid prema zahtjevu 12.
14. Postupak proizvodnje protutijela ili fragmenta protutijela prema bilo kojem od zahtjeva 1 do 7, naznačen time da sadrži kulturu stanica domaćina prema zahtjevu 13, i obnavljanje koje proizlazi iz istog protutijela ili fragment protutijela prema bilo kojem od zahtjeva 1 do 7.
15. Postupak za pripravu varijante protutijela ili njegov fragment prema bilo kojem zahtjevu 1 do 7, naznačen time da spomenuta varijanta sadrži mogućnost vezanja na fosforilkolin, te postupak sadrži slijedeće korake
(i) dobivanje nukleinske kiseline prema zahtjevu 11 koja kodira roditeljsko protutijelo ili fragment protutijela;
(ii) uvođenja jedne ili više nukleotidnih mutacija u regiji koje kodiraju aminokiseline sekvenci aminokiselina, opcijski unutar regija kodiranja VH i/ili VL domene(a), tako da mutirana nukleinska kiselina kodira drugačije protutijelo ili fragment protutijela koji ima različitu sekvencu aminokiseline u odnosnu na roditeljsko protutijelo ili fragment protutijela.
(iii) izražavanje različitog protutijela ili fragmenta protutijela koji je kodiran sekvencom mutirane nukleinske kiseline ; i
(iv) uspoređivanje sposobnosti različitog protutijela ili fragmenta protutijela i roditeljskog protutijela ili fragment protutijela za vezanje na fosforilkolin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161521593P | 2011-08-09 | 2011-08-09 | |
| EP12747915.2A EP2742068B1 (en) | 2011-08-09 | 2012-08-08 | New antibodies against phosphorylcholine |
| PCT/EP2012/065505 WO2013020995A1 (en) | 2011-08-09 | 2012-08-08 | New antibodies against phosphorylcholine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190988T1 true HRP20190988T1 (hr) | 2019-09-20 |
Family
ID=46679261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190988TT HRP20190988T1 (hr) | 2011-08-09 | 2019-05-30 | Nova protutijela protiv fosforilkolina |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9803028B2 (hr) |
| EP (1) | EP2742068B1 (hr) |
| JP (1) | JP6277125B2 (hr) |
| KR (1) | KR101947758B1 (hr) |
| CN (1) | CN104039832B (hr) |
| AR (1) | AR087485A1 (hr) |
| AU (1) | AU2012293646B2 (hr) |
| BR (1) | BR112014002929A8 (hr) |
| CA (1) | CA2843921A1 (hr) |
| CY (1) | CY1121950T1 (hr) |
| DK (1) | DK2742068T3 (hr) |
| ES (1) | ES2732838T3 (hr) |
| HK (1) | HK1200852A1 (hr) |
| HR (1) | HRP20190988T1 (hr) |
| HU (1) | HUE045163T2 (hr) |
| LT (1) | LT2742068T (hr) |
| MX (1) | MX364425B (hr) |
| PL (1) | PL2742068T3 (hr) |
| PT (1) | PT2742068T (hr) |
| RS (1) | RS58986B1 (hr) |
| RU (1) | RU2654584C2 (hr) |
| SG (1) | SG2014009344A (hr) |
| SI (1) | SI2742068T1 (hr) |
| TR (1) | TR201909072T4 (hr) |
| TW (1) | TWI707873B (hr) |
| WO (1) | WO2013020995A1 (hr) |
| ZA (1) | ZA201400665B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2843960C (en) | 2011-08-09 | 2020-09-15 | Athera Biotechnologies Ab | Antibodies binding to phosphorylcholine (pc) and/or pc conjugates |
| PL2742068T3 (pl) * | 2011-08-09 | 2020-01-31 | Athera Biotechnologies Ab | Nowe przeciwciała przeciwko fosforylcholinie |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| CA2979361A1 (en) | 2015-03-09 | 2016-09-15 | Caris Science, Inc. | Method of preparing oligonucleotide libraries |
| EP3314027A4 (en) | 2015-06-29 | 2019-07-03 | Caris Science, Inc. | THERAPEUTIC OLIGONUCLEOTIDES |
| AU2016298317B2 (en) | 2015-07-28 | 2021-02-18 | Caris Science, Inc. | Targeted oligonucleotides |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2402664A1 (fr) | 1977-09-07 | 1979-04-06 | Agronomique Inst Nat Rech | Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications |
| US5955584A (en) | 1986-03-31 | 1999-09-21 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| ES2070820T3 (es) | 1986-08-06 | 1995-06-16 | Scripps Clinic Res | Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas. |
| JPH02188532A (ja) | 1989-01-17 | 1990-07-24 | Otsuka Pharmaceut Co Ltd | リポソームワクチン |
| WO1990012632A1 (en) | 1989-04-19 | 1990-11-01 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids |
| JP3283041B2 (ja) | 1990-07-13 | 2002-05-20 | 学校法人藤田学園 | 人工抗体 |
| WO1992010203A1 (en) | 1990-12-10 | 1992-06-25 | Alving Carl R | A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis |
| RU2014609C1 (ru) * | 1991-06-06 | 1994-06-15 | Московский институт тонкой химической технологии им.М.В.Ломоносова | Способ определения белков, специфичных к фосфорилхолину |
| CA2131150A1 (en) | 1992-03-03 | 1993-09-16 | Michel C. Nussenzweig | Receptor complexes with b29 (ig-beta or ig-gamma) and their uses |
| AU5959494A (en) | 1992-12-29 | 1994-07-19 | Entremed, Inc | Vaccines against sterols |
| DE69411154T2 (de) | 1993-02-22 | 1998-10-22 | Alza Corp., Palo Alto, Calif. | Mittel zur oralen gabe von wirkstoffen |
| US5455032A (en) | 1993-07-29 | 1995-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Use of phosphocholine hapten conjugates in vaccines |
| US6375925B1 (en) | 1996-11-08 | 2002-04-23 | The Regents Of The University Of California | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
| AU1159497A (en) | 1996-11-08 | 1998-06-03 | Regents Of The University Of California, The | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
| US6225070B1 (en) | 1997-08-07 | 2001-05-01 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma |
| US20040185039A1 (en) | 2002-08-30 | 2004-09-23 | Heinz Kohler | Therapeutic applications of noncovalent dimerizing antibodies |
| US6300308B1 (en) | 1997-12-31 | 2001-10-09 | Board Of Regents, The University Of Texas System | Methods and compositions for inducing autoimmunity in the treatment of cancers |
| SE9802402D0 (sv) | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
| DK1095271T3 (da) | 1998-07-03 | 2003-12-15 | Athera Biotechnologies Ab | Fremgangsmåde til diagnose af hjertekar-sygdomme og tidlig aterosklerose |
| CA2389849A1 (en) | 1999-10-26 | 2001-05-10 | Regents Of The University Of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| SE0000855D0 (sv) | 2000-03-15 | 2000-03-15 | Karolinska Innovations Ab | Antigenic composition useful as a vaccine against atherosclerosis |
| AU2001259730A1 (en) | 2000-05-12 | 2001-11-26 | The Regents Of The University Of California | Standardized oxidized ldl assay |
| DE10041515A1 (de) | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| SE0103754L (sv) | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| WO2004091520A2 (en) | 2003-04-11 | 2004-10-28 | The Regents Of The University Of California | Methods and compositions for treating atherosclerosis |
| AU2005233361B2 (en) | 2004-04-15 | 2011-02-24 | Athera Biotechnologies Ab | Phosphorylcholine conjugates and corresponding antibodies |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| EP1868651A4 (en) | 2005-04-12 | 2010-10-06 | Univ Duke | METHOD FOR INDUCING ANTIBODIES THAT NEUTRALIZE THE HUMAN IMMUNODEFICIENCY VIRUS |
| AU2006330807A1 (en) | 2005-11-28 | 2007-07-05 | Medimmune, Llc | Antagonists of HMBG1 and/or rage and methods of use thereof |
| WO2008150485A2 (en) | 2007-05-29 | 2008-12-11 | Wyeth | Erbb2 binding proteins and use thereof |
| JP5122908B2 (ja) | 2007-10-17 | 2013-01-16 | 日泉化学株式会社 | 自動車の内装用部材の取り付け構造 |
| WO2010003602A1 (en) | 2008-07-07 | 2010-01-14 | Athera Biotechnologies Ab | New therapeutic and diagnostic methods for alzheimer's disease |
| WO2012010291A1 (en) | 2010-07-21 | 2012-01-26 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for metabolic disease |
| KR102502293B1 (ko) | 2011-01-06 | 2023-02-21 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| CA2843960C (en) | 2011-08-09 | 2020-09-15 | Athera Biotechnologies Ab | Antibodies binding to phosphorylcholine (pc) and/or pc conjugates |
| PL2742068T3 (pl) * | 2011-08-09 | 2020-01-31 | Athera Biotechnologies Ab | Nowe przeciwciała przeciwko fosforylcholinie |
-
2012
- 2012-08-08 PL PL12747915T patent/PL2742068T3/pl unknown
- 2012-08-08 TR TR2019/09072T patent/TR201909072T4/tr unknown
- 2012-08-08 SG SG2014009344A patent/SG2014009344A/en unknown
- 2012-08-08 WO PCT/EP2012/065505 patent/WO2013020995A1/en active Application Filing
- 2012-08-08 CN CN201280049552.0A patent/CN104039832B/zh not_active Expired - Fee Related
- 2012-08-08 TW TW101128575A patent/TWI707873B/zh not_active IP Right Cessation
- 2012-08-08 KR KR1020147006274A patent/KR101947758B1/ko active IP Right Grant
- 2012-08-08 LT LTEP12747915.2T patent/LT2742068T/lt unknown
- 2012-08-08 MX MX2014001313A patent/MX364425B/es active IP Right Grant
- 2012-08-08 CA CA2843921A patent/CA2843921A1/en not_active Abandoned
- 2012-08-08 SI SI201231604T patent/SI2742068T1/sl unknown
- 2012-08-08 JP JP2014524371A patent/JP6277125B2/ja not_active Expired - Fee Related
- 2012-08-08 DK DK12747915.2T patent/DK2742068T3/da active
- 2012-08-08 HU HUE12747915A patent/HUE045163T2/hu unknown
- 2012-08-08 EP EP12747915.2A patent/EP2742068B1/en active Active
- 2012-08-08 RU RU2014108815A patent/RU2654584C2/ru active
- 2012-08-08 US US14/237,035 patent/US9803028B2/en active Active
- 2012-08-08 AU AU2012293646A patent/AU2012293646B2/en not_active Ceased
- 2012-08-08 ES ES12747915T patent/ES2732838T3/es active Active
- 2012-08-08 RS RS20190807A patent/RS58986B1/sr unknown
- 2012-08-08 AR ARP120102895A patent/AR087485A1/es unknown
- 2012-08-08 BR BR112014002929A patent/BR112014002929A8/pt not_active Application Discontinuation
- 2012-08-08 PT PT12747915T patent/PT2742068T/pt unknown
-
2014
- 2014-01-28 ZA ZA2014/00665A patent/ZA201400665B/en unknown
-
2015
- 2015-02-05 HK HK15101305.1A patent/HK1200852A1/xx unknown
-
2017
- 2017-09-28 US US15/719,520 patent/US20180086848A1/en not_active Abandoned
-
2019
- 2019-05-30 HR HRP20190988TT patent/HRP20190988T1/hr unknown
- 2019-06-28 CY CY20191100683T patent/CY1121950T1/el unknown
-
2021
- 2021-04-13 US US17/229,837 patent/US20210238311A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190988T1 (hr) | Nova protutijela protiv fosforilkolina | |
| JP2020023523A5 (hr) | ||
| HRP20201375T1 (hr) | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE | |
| JP2015501814A5 (hr) | ||
| JP2020018311A5 (hr) | ||
| JP2019500862A5 (hr) | ||
| JP2020124209A5 (hr) | ||
| HRP20192160T1 (hr) | Vezujući proteini serumskog albumina | |
| JP2017052784A5 (hr) | ||
| JP2014518883A5 (hr) | ||
| JP2017114866A5 (hr) | ||
| JP2014503189A5 (hr) | ||
| HRP20151213T1 (hr) | Anti-c5a protutijela i postupci za uporabu protutijela | |
| JP2020503001A5 (hr) | ||
| RU2016115866A (ru) | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи | |
| CA2818635C (en) | Antibodies selective for cells presenting erbb2 at high density | |
| JP2012070737A5 (hr) | ||
| JP2014530001A5 (hr) | ||
| JP2013535190A5 (hr) | ||
| JP2015525211A5 (hr) | ||
| JP2021501744A5 (hr) | ||
| JP2016514463A5 (hr) | ||
| JP2012500815A5 (hr) | ||
| JP2010526028A5 (hr) | ||
| JP2012502649A5 (hr) |